Position Papers & Editorials

 EANM position paper: theranostics in brain tumours—the present and the future. (2023)

 How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation. (2023)

 Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry (2023)

 FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective. (2023)

 European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees. (2022)

 European consensus for the diagnosis of MCI and mild dementia: Preparatory phase. (2022)

 An EANM position paper on advancing radiobiology for shaping the future of nuclear medicine. (2022)

 An EANM position paper on the application of artificial intelligence in nuclear medicine (2022)

 Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation (2022)

 SNMMI/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management—the EANM perspective (2022)

 Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM (2022)

 2-[ 18 F]-FDG PET for imaging brain involvement in patients with long COVID: perspective of the EANM Neuroimaging Committee (2022)

 2022 follow-up: impact of the COVID-19 pandemic on nuclear medicine departments in Europe (2022)

 EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA) (2022)

 EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy (2022)

 Gender issues in the nuclear medicine community: results from a survey promoted by the EANM Women Empowerment Task Force (2022)

 EANM position on the in-house preparation of radiopharmaceuticals (2022)

 Impact of the COVID-19 pandemic on nuclear medicine departments in Europe (2021)

 The approval of a disease-modifying treatment for Alzheimer’s disease: impact and consequences for the nuclear medicine community (2021)

EANM position paper on the role of radiobiology in nuclear medicine (2021)

 Position paper of the EACVI and EANM on artificial intelligence applications in multimodality cardiovascular imaging using SPECT/CT, PET/CT, and cardiac CT (2021)

EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy: 67-72 (2021)

 EANM Focus 3: The International Conference on Molecular Imaging and Theranostics in Neuroendocrine Tumours—the consensus in a nutshell (2021). Official EANM editorial summarising the highlights of the EANM FOCUS 3 consensus meeting publication.

 Consensus on molecular imaging and theranostics in neuroendocrine neoplasms (2021). Official EANM consensus paper of FOCUS Meeting 3.

Finding our way through the labyrinth of dementia biomarkers (2021). Official EANM editorial summarising the highlights of the EANM FOCUS 2 consensus meeting publication. 

 Amyloid-PET and ¹⁸F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias (2020). Official EANM consensus paper of FOCUS Meeting 2.

A joint procedural position statement on imaging in cardiac sarcoidosis: From the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology (2018)

 Consensus on molecular imaging and theranostics in prostate cancer (2018). Official EANM consensus paper of FOCUS Meeting 1.

A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology (2017)

Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals (2017)

Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis (2015)

Reporting nuclear cardiology: A joint position paper by the European Association of Nuclear Medicine (EANM) and the European Association of Cardiovascular Imaging (EACVI) (2015)